Testosterone Pellet Use in Transgender Men.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
ACS Applied Bio Materials Pub Date : 2023-12-13 eCollection Date: 2023-12-01 DOI:10.1089/trgh.2021.0205
Kwan Cheng, Aren Skolnick
{"title":"Testosterone Pellet Use in Transgender Men.","authors":"Kwan Cheng, Aren Skolnick","doi":"10.1089/trgh.2021.0205","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We assessed the efficacy and short-term adverse effects of testosterone pellet use in transgender men to broaden therapeutic options.</p><p><strong>Methods: </strong>We conducted a retrospective study of 30 transgender men who started testosterone pellets between 2018 and 2020.</p><p><strong>Results: </strong>Testosterone pellets were started at dosages 675-825 mg per cycle and dose was adjusted according to testosterone levels obtained 1 to 6 months post-testosterone pellet insertion. Pharmacokinetics of testosterone pellet in transgender men was similar to those in cisgender men. Total testosterone levels reached a peak in 1 month and remained in the therapeutic range for ∼4 months in the range of 300-800 ng/dL. After switching over to testosterone pellets, 100% of patients continued to achieve amenorrhea and deepening of their voice. Most of the patients noticed increased hair growth in androgen-dependent regions (96.3%) and improved libido (70%). Adverse events were notable for a rate of polycythemia that was unexpectedly high at 46.67%. Pellet extrusion was found in 13.33% of patients. There was a low rate of pellet site hematoma (6.67%) and cellulitis (3.33%). No thromboembolic or cardiovascular events occurred in any of the patients.</p><p><strong>Conclusion: </strong>This study reveals that testosterone pellets are a reasonable alternative to other testosterone modalities in transgender men but would use caution in patients with a history of polycythemia or higher risk for thromboembolic events.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732158/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/trgh.2021.0205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: We assessed the efficacy and short-term adverse effects of testosterone pellet use in transgender men to broaden therapeutic options.

Methods: We conducted a retrospective study of 30 transgender men who started testosterone pellets between 2018 and 2020.

Results: Testosterone pellets were started at dosages 675-825 mg per cycle and dose was adjusted according to testosterone levels obtained 1 to 6 months post-testosterone pellet insertion. Pharmacokinetics of testosterone pellet in transgender men was similar to those in cisgender men. Total testosterone levels reached a peak in 1 month and remained in the therapeutic range for ∼4 months in the range of 300-800 ng/dL. After switching over to testosterone pellets, 100% of patients continued to achieve amenorrhea and deepening of their voice. Most of the patients noticed increased hair growth in androgen-dependent regions (96.3%) and improved libido (70%). Adverse events were notable for a rate of polycythemia that was unexpectedly high at 46.67%. Pellet extrusion was found in 13.33% of patients. There was a low rate of pellet site hematoma (6.67%) and cellulitis (3.33%). No thromboembolic or cardiovascular events occurred in any of the patients.

Conclusion: This study reveals that testosterone pellets are a reasonable alternative to other testosterone modalities in transgender men but would use caution in patients with a history of polycythemia or higher risk for thromboembolic events.

睾酮颗粒在变性男性中的应用
目的:我们评估了变性男性使用睾酮颗粒的疗效和短期不良反应,以扩大治疗选择:我们对2018年至2020年间开始服用睾酮颗粒的30名变性男性进行了回顾性研究:睾酮颗粒的起始剂量为每个周期675-825毫克,剂量根据睾酮颗粒植入后1-6个月获得的睾酮水平进行调整。变性男性服用睾酮颗粒的药代动力学与同性男性相似。总睾酮水平在 1 个月内达到峰值,并在 300-800 纳克/分升的治疗范围内维持了 4 个月。在改用睾酮颗粒后,100% 的患者继续实现闭经,嗓音加深。大多数患者注意到雄激素依赖区的毛发生长增加(96.3%),性欲提高(70%)。值得注意的是,多血症的发生率出乎意料地高,达到 46.67%。13.33%的患者出现了颗粒挤出。颗粒部位血肿(6.67%)和蜂窝组织炎(3.33%)发生率较低。所有患者均未发生血栓栓塞或心血管事件:这项研究表明,在变性男性中,睾酮颗粒是其他睾酮方式的合理替代品,但对于有多血症病史或血栓栓塞事件风险较高的患者,应谨慎使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信